公告内容

ADDF Supports 马德拉 Biosciences to Advance Small Molecule Drugs that Upregulate APOE

2013年6月12日

类别:新赠款

老年痴呆症's Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to 马德拉 Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt or reverse the progression of Alzheimer's disease.

马德拉 has identified a series of proprietary, small molecule compounds that increase the expression of apolipoprotein E (APOE), which has been shown to mediate beta-amyloid clearance from the brain and prevent its accumulation into the plaques that are characteristic of Alzheimer'的疾病。 APOE是在血液和大脑中循环的脂质结合蛋白。在动物模型中,增加脑细胞载脂蛋白E的释放已显示可减少β-淀粉样蛋白斑块并改善认知功能。

马德拉'新型的类药物化合物可促进apoE的释放,可能有助于β-淀粉样蛋白的清除过程,并被认为可以改善症状,减缓阿尔茨海默氏症的进展's disease and potentially reverse the course of the disease. 马德拉’该铅化合物具有极好的暴露能力,建议每天给药一次,并具有脑渗透能力,使药物进入大脑,从而增加apoE的产生。 ADDF's funding will allow 马德拉 to advance these compounds for proof-of-concept testing in animal models of Alzheimer's disease.

“我们很高兴继续与ADDF合作,以改进这些有前途的口服化合物。ADDF'支持对于实现我们提供老年痴呆症的目标至关重要's patients a therapy that changes the course of the disease," said Rick Jack, Ph.D., Chief Executive Officer for 马德拉. "These funds will allow us to gain a better in vivo understanding of how our compounds affect the pathologies caused by beta-amyloid deposition."

"马德拉'增强分泌的独特方法APOE作为治疗阿尔茨海默氏症的方法很有前途'ADDF执行董事兼首席科学官霍华德·菲利特(Howard Fillit)医师说:“由于APOE是阿尔茨海默氏症的主要已知危险因素,'疾病(衰老后),根据我们对APOE生物学的了解开发治疗剂是我们领域的关键挑战。”

据估计,在美国有超过500万患者,全世界有3500万患者患有阿尔茨海默氏症'的疾病。据信这种疾病每年对美国的医疗保健产生1720亿美元的影响,预计在不久的将来会迅速增加。